Belluscura’s X-PLO₂R™ receives top award at US trade show

Francesca Morgan
Vox Newswire
09:11, 25th October 2021


Belluscura(BELL FOLLOW) announced that its X-PLO₂R™ portable oxygen concentrator has won the Providers’ Choice Gold, the highest accolade to be given at Medtrade East 2021 in Atlanta.

Medtrade East is the largest home medical equipment trade show and conference in the U.S.

The medical device developer, which is focused on lightweight and portable oxygen enrichment technology, says X-PLO₂R™ is the first modular portable oxygen concentrator.

The X-PLO₂R™ weighs less than 1.5kg (3.25lbs) and can deliver up to 95% pure oxygen to patients 24 hours a day, 7 days a week. In fact, the Company explained that the X-PLO₂R™ can generate more oxygen by weight than any other US FDA cleared POC in its class. 

X-PLO₂R™, which commenced manufacturing in the US this July, was created to improve the quality of life for millions of people worldwide who suffer from chronic lung diseases, such as Chronic Obstructive Pulmonary Disease and respiratory distress caused by COVID-19. 

Addressing shareholders last week, Robert Rauker, Chief Executive Officer of Belluscura, said that initial demand for the X-PLO2R™ had been “excellent”.  The X-

PLO₂R™ is designed to replace larger, metal oxygen tanks and heavier portable oxygen concentrator devices.

Today, Rauker described the accolade as “fantastic news” and “a great achievement”. “This award solidifies the strong demand we are receiving for the product and we will update shareholders with expected unit deliveries for 2021 and 2022 in the near future,” he stated.

Last week, Belluscura announced that it had signed its fifth distribution agreement with an unnamed online partner, to distribute its X-PLO₂R™ product across the United States.

At the time, the Company said the US client, which has already placed its first orders with Belluscura, is a ‘leading online distributor, located in Colorado, Arizona and Georgia’.

Belluscura also describes its online partner as being a ‘significant presence’ in the portable concentrated oxygen market which has cumulatively served over 100,000 customers.

This distribution agreement is considered significant by Belluscura because it means the Company has exceeded the initial commercial launch target for X-PLO₂R™ unit sales. 

Belluscura said it demonstrates that its management team is successfully delivering on its commercialisation strategy while also highlighting ‘the evident market anticipation for  X-PLO₂R™ and its ability to significantly improve the current standard-of-care,’ it noted.

In July, the Company said manufacturing had commenced in the United States for the first X-PLO2R™ units ahead of their planned distribution which had been on target for 3Q21.  

Last month, Belluscura said initial demand for X-PLO₂R™, the world’s first modular portable oxygen concentrator, had been “strong” since the first units were distributed to customers.

“Receiving FDA 510(k) Clearance for the X-PLO2R™ was pivotal for the Group, followed by an oversubscribed placing and successful listing in May. To have brought the product to market so quickly is a tremendous achievement,” commented Chairman, Adam Reynolds in the Company’s recently published half-year results for the six months to 30 June 2021.

Last month, Reynolds said the initial response from the market was “hugely positive” to date.

BELL price chart

View from Vox

As described in the Company’s original admission document, Belluscura’s strategy is to appoint distributors in the United States to give US-wide coverage for the launch of the X-PLO2R; and this is expected to occur in the second half of 2021 and into 2022.

Belluscura’S X-PLO₂R weighs less than 1.5kg (3.25lbs) and the Directors believe it is the world’s first modular portable oxygen concentrator and that it will generate more oxygen by weight than any other US Food & Drug Administration (“FDA”) cleared POC in its class. 

The X-PLO₂R can deliver up to 95% pure oxygen to patients 24 hours a day, 7 days a week to help improve the quality of life for millions of people who suffer from chronic lung diseases, such as Chronic Obstructive Pulmonary Disease and COVID-19 related respiratory distress. 

Belluscura said it has confidence for 2021 and beyond after receiving early interest from distributors in the US, Europe, South America and Asia, wanting to supply the X-PLO2R™. 

Rauker has described having the group’s X-PLO2R™ portable oxygen concentrator available through a Service-Disabled Veteran-Owned Small Business is “a tremendous opportunity.”  

Following a US launch the Company intends, in due course, to pursue commercialisation across the UK, EU, Japan, South Asia, Australia, South America and Latin America.   

As part of its commercialisation strategy for X-PLO₂R portfolio, the Directors of Bellascura have adopted a five-phase process which will commence with its initial launch in July 2021. 

The global respiratory care devices market is estimated to be $23.4 billion in 2021 with the market expected to reach $28.6 billion by 2024, growing over $1.7 billion per year.   

Within this wider market, the supplemental oxygen therapy devices market was forecast in 2018 to grow by 6% per year from $3.2bn in 2021 to $4.2 bn by 2026 and the impact of the COVID-19 pandemic has led to an increase in this growth forecast to 11% per annum.  

As a result, the market is now forecast to reach $5.7bn by 2026, an increase of 66% over the next 5 years. In fact, to give a scope of this market, the World Health

Organisation (“WHO”) announced on 24 June 2020 that it would be purchasing 184,000 oxygen concentrators, valued at over $100 million, in order to address oxygen shortages across 120 countries.   

Follow News & Updates from Belluscura here: FOLLOW


Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Login or register to post comments

Recent Articles